Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 2

6(75.0%)

Phase 1

2(25.0%)

8Total

Phase 2(6)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06534437Phase 2Recruiting

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Role: lead

NCT06987058Phase 2Not Yet Recruiting

RVU120 Rollover Study

Role: lead

NCT06397313Phase 2Recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis

Role: lead

NCT06243458Phase 2Active Not Recruiting

RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms

Role: collaborator

NCT06268574Phase 2Active Not Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Role: lead

NCT06191263Phase 2Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML

Role: lead

NCT05052255Phase 1Active Not Recruiting

RVU120 (SEL120) in Patients with Relapse/Refractory Metastatic or Advanced Solid Tumors

Role: lead

NCT04021368Phase 1Unknown

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Role: lead

All 8 trials loaded